Insulin aspart, recombinant Subcutaneous and Ocrelizumab Intravenous
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Ocrelizumab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: ocrelizumab
Brand name: Ocrevus
Synonyms: Ocrelizumab (Intravenous), Ocrelizumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Ocrevus
- Insulin aspart, recombinant Subcutaneous-Octagam
- Insulin aspart, recombinant Subcutaneous-Octagam Gammagard S/D
- Insulin aspart, recombinant Subcutaneous-Octocaine
- Insulin aspart, recombinant Subcutaneous-Octocaine 100
- Insulin aspart, recombinant Subcutaneous-OctreoScan
- Ocrelizumab Intravenous-Insulin degludec
- Ocrelizumab Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Ocrelizumab Intravenous-Insulin Degludec (U-100) Vials
- Ocrelizumab Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Ocrelizumab Intravenous-Insulin degludec and liraglutide
- Ocrelizumab Intravenous-Insulin degludec and liraglutide Subcutaneous